ARK Venture Fund on Tuesday disclosed it took part in the Series D financing round of Cellares, a contract development and manufacturing organization focused on cell therapies. The investment comes as Cellares advances an automated production approach intended to replace manual, small-batch processes with industrial-scale automation.
Cellares has developed the Cell Shuttle system, an automated platform intended for both manufacturing and quality control of cell therapies. The company positions the technology as an alternative to manual manufacturing workflows that it says are a bottleneck to scaling these treatments.
"The science behind cell therapy is proven. The challenge now is manufacturing these life-saving treatments at the scale and cost required to meet patient demand," said Cathie Wood, Founder, CEO, and CIO of ARK Invest.
In April, Cellares used the Cell Shuttle platform to manufacture and deliver the first two GMP doses of rese-cel, Cabaletta Bio’s investigational CAR T cell therapy. According to the company, both doses met all release specifications and were infused into patients on schedule.
Also in April, Cabaletta Bio entered a 10-year commercial supply agreement with Cellares to scale manufacture of rese-cel. These announcements follow a separate $380 million global manufacturing agreement with Bristol Myers Squibb, under which commercial-scale manufacturing capacity in the United States, Europe, and Japan is reserved for Bristol Myers Squibb’s cell therapy programs.
Cellares currently operates facilities in South San Francisco, California and Bridgewater, New Jersey. The company is developing additional sites in Leiden, the Netherlands and Kashiwa City, Japan. Cellares says the network is designed to enable commercial-scale cell therapy production for hundreds of thousands of patients annually beginning in 2027.
Key points
- ARK Venture Fund invested in Cellares' Series D round as the company pushes to industrialize cell therapy manufacturing - sectors impacted include biotech manufacturing and healthcare delivery.
- Cellares' Cell Shuttle platform has been used to produce two GMP rese-cel doses for Cabaletta Bio, and the company signed a 10-year commercial supply agreement to scale that therapy - this affects contract manufacturing and commercial supply chains in cell therapy.
- A $380 million global manufacturing agreement with Bristol Myers Squibb reserves commercial-scale capacity across the US, Europe, and Japan, supporting planned global expansion.
Risks and uncertainties
- Timing risk - Cellares' global network is intended to enable commercial-scale production beginning in 2027; the company must execute on facility development and scale-up to meet that target - this impacts capital-intensive manufacturing and biotech commercialization timelines.
- Execution risk - converting automated platform capabilities into repeatable, regulated commercial production at scale remains an operational challenge; this affects contract manufacturing and regulatory compliance in the life sciences sector.
- Geographic expansion uncertainty - facilities in Leiden and Kashiwa City are under development, and their build-out and commissioning timelines could influence the company's ability to meet reserved capacity commitments in multiple regions.
The ARK Venture Fund investment underscores investor interest in technologies that aim to lower the logistical and cost barriers to broader access for cell therapies. Cellares' recent production milestones and multi-year supply agreements mark steps toward its stated goal of commercial-scale manufacturing capacity, while the company continues to expand its facility footprint internationally.